CN101558794A - Composition with functions of lowering blood lipid and regulating blood sugar and preparation method thereof - Google Patents
Composition with functions of lowering blood lipid and regulating blood sugar and preparation method thereof Download PDFInfo
- Publication number
- CN101558794A CN101558794A CNA2008100933766A CN200810093376A CN101558794A CN 101558794 A CN101558794 A CN 101558794A CN A2008100933766 A CNA2008100933766 A CN A2008100933766A CN 200810093376 A CN200810093376 A CN 200810093376A CN 101558794 A CN101558794 A CN 101558794A
- Authority
- CN
- China
- Prior art keywords
- oil
- composition
- haiyingcai
- vitamin
- seed oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition with health-care function, which is prepared by the following raw materials by weight percent: 99.95-99.99 of common seepweed herb rap oil and 0.01-0.05 of antioxidant, wherein the antioxidant is one kind or several kinds of butyl hydroxy anisol, tert-butyl hydroquinone, dibutyl hydroxy toluene, propyl gallate, Vitamin C, Vitamin E and citric acid; and 5-40 percent of the common seepweed herb rap oil can be replaced by one kind or several kinds of fish oil, evening primrose oil, perilla herb oil, teaseed oil, palm oil, maize germ, walnut-meat oil, olive oil and canola oil. The composition has the functions of lowering blood lipid, regulating blood sugar and strengthening immunity and can be prepared into soft capsule or oral solution.
Description
Technical field
The present invention relates to a kind of composition, particularly a kind of composition and method of making the same and purposes that has reducing blood lipid, adjusting blood sugar, strengthens immunity with health care.
Background technology
Along with growth in the living standard, people's dietary fat intake increases, fatty energy supply has surpassed 30% of gross energy in some crowds, regulates the disease of blood fat to prevent hyperlipemia and to be caused by natural food, has become the focus of current Food Science and medical health field research.
Unrighted acid is a kind of aliphatic acid that constitutes body fat, also is the aliphatic acid of needed by human.Unrighted acid has the flowability relatively that keeps cell membrane, to protect the normal physiological function of positive cell, make the cholesterol esterification, reduce blood cholesterol and triglycerides, reduce blood viscosity, improve physiological functions such as blood microcirculation, unrighted acid still is the precursor matter of interior prostaglandin of synthesized human and thromboxane.Unrighted acid is divided into two kinds of monounsaturated fatty acids and polyunsaturated fatty acids according to the difference of two key numbers.In food fat, monounsaturated fatty acids has oleic acid, and polyunsaturated fatty acid has linoleic acid, leukotrienes, arachidonic acid etc.Human body can not synthesize linoleic acid plus linolenic acid, must replenish from meals.Owing to contain, become the food of people's favor in fish oil, evening primrose oil, perilla herb oil, tea oil, palm oil, maize germ, Semen Juglandis oil, olive oil, the mustard caul-fat etc. than polyunsaturated fatty acid.
HAIYINGCAI (having another name called " alkali is fluffy ") is an annual herb salification plant, botany classification is Chenopodiaceae (chenopodiace-ae) Suaeda (suaedaforsk.exscop), mainly growing in the saline-alkali wasteland that beach, lakeside, desert etc. are located, is a kind of typical salt-soda soil indicator plant.
According to inventor's research, HAIYINGCAI seed oil croude fatty acids content can be up to more than 20%, and linoleic acid content reaches 70% in the aliphatic acid, and alpha-linolenic acid can reach 6%, and total unrighted acid reaches more than 90%.Linoleic acid and alpha-linolenic acid are the essential fatty acids that human growth is grown, and HAIYINGCAI seed oil also contains vitamin E, sterol and the CLA that human health is highly profitable.18 carbon fatty acids account for 90% in the HAIYINGCAI seed oil, are a kind of very rare raw-food materials.Utilize the HAIYINGCAI seed to produce high-grade nutrient edible oil or health food, have vast market prospect.
But, because HAIYINGCAI seed oil is rich in unrighted acid, very easily oxidation takes place and becomes sour rotten in processing, storage and sales process.Study repeatedly through the inventor, the present invention has overcome HAIYINGCAI seed oil easily oxidation and the technological deficiency of becoming sour, a kind of composition that contains HAIYINGCAI seed oil is provided, can effectively prevent its oxidation deterioration, simultaneously, this composition has tangible reducing blood lipid, adjusting blood sugar, strengthens the effect of immunity, and the present invention also provides the method for this composition being made preparation, not only improved the stability of composition more, and be convenient to carry, take.
Summary of the invention
The invention provides a kind of composition and method of making the same that has reducing blood lipid, adjusting blood sugar, strengthens immunity.
The objective of the invention is to be achieved by the following scheme:
The invention provides a kind of composition that has reducing blood lipid, adjusting blood sugar, strengthens immunity, said composition is to be made by the raw material that comprises following weight portion:
(1) HAIYINGCAI seed oil 99.95%～99.99%,
(2) antioxidant 0.01%～0.05%;
Wherein, the antioxidant in the composition is one or more in butylated hydroxy anisole (BHA), TBHQ (TBHQ), dibutyl hydroxy toluene (BHT), n-propyl gallate (PC) and vitamin C (VC), vitamin E (VE), the citric acid;
The HAIYINGCAI seed oil of 5%～40% weight portion can substitute with in fish oil, evening primrose oil, perilla herb oil, tea oil, palm oil, maize germ, Semen Juglandis oil, olive oil, the mustard caul-fat one or more in the present composition.
The invention described above composition can adopt but be not limited only to following technical scheme:
Technical scheme one: the present composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 99.95%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.05%.
Technical scheme two: the present composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 99.97%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.03%.
Technical scheme three: the present composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 99.99%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.01%.
Technical scheme four: the present composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 59.95%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.05%,
(3) fish oil and evening primrose oil and/or perilla herb oil and/or tea oil and/or palm oil and/or maize germ and/or Semen Juglandis oil and/or olive oil and/or mustard caul-fat 40%.
Technical scheme five: the present composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 74.97%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.03%,
(3) fish oil and evening primrose oil and/or perilla herb oil and/or tea oil and/or palm oil and/or maize germ and/or Semen Juglandis oil and/or olive oil and/or mustard caul-fat 25%.
Technical scheme six: the present composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 94.99%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.01%,
(3) fish oil and evening primrose oil and/or perilla herb oil and/or tea oil and/or palm oil and/or maize germ and/or Semen Juglandis oil and/or olive oil and/or mustard caul-fat 5%.
The present invention also provides the preparation method of above-mentioned composition preparation: according to the pharmaceutical preparation technology of routine, be prepared into soft capsule and oral liquid formulations.
Above-mentioned formulation preferably be: soft capsule.
The vegetable oil of HAIYINGCAI seed oil for extracting in Chenopodiaceae (chenopodiace-ae) Suaeda (suaedaforsk.exscop) vegetable seeds in the present composition.
The present composition has reducing blood lipid, regulates blood sugar, strengthens immunity.
Beneficial effect of the present invention:
1, the invention provides the composition that a kind of HAIYINGCAI seed oil and antioxidant mix, this composition can effectively prevent the oxidation deterioration of HAIYINGCAI seed oil, and this composition has the effect of reducing blood lipid, adjusting blood sugar, raising immunity.
2, because HAIYINGCAI seed oil contains a large amount of unrighted acids, and unrighted acid is a liquid, so soft capsule and oral liquid are the formulations that comparatively is fit to.And unrighted acid has very strong reproducibility, very easily by the oxidation of airborne oxygen institute, because the capsule skin of soft capsule is thicker, has good protective effect to preventing that active material is oxidized, so present composition preferred dosage form is a soft capsule.
3, the soft capsule of the present composition is totally-enclosed formulation, has reduced the chance of polluting, and has guaranteed the hygiene quality of the present composition.
4, the present composition is made soft capsule, need not add other excipients, does not contain sugar, is convenient to the elderly, the diabetic takes.
5, the present composition is made soft capsule, and formulation is refining, attractive in appearance, mouthfeel is good, dose is few, be convenient to take, easy to carry, satisfies modern's living needs more.
6, the present composition is made soft capsule bioavilability height, and the active material that is comprised is that the form with dispersion exists, and fully disperses with matrix, enters the rapid disintegration of stomach and intestine and is absorbed by the body, and reaches effective blood drug concentration and produce effects.
The specific embodiment
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
Experimental example 1: the anti-oxidant experimental study of HAIYINGCAI seed oil
Because HAIYINGCAI seed oil is rich in unrighted acid, very easily oxidation takes place and become sour rotten in processing, storage and sales process.The inventor has carried out the oxidation resistant experimental study of HAIYINGCAI seed oil for this reason.
1. materials and methods
1.1 material
HAIYINGCAI seed oil: extract refining and get from the HAIYINGCAI seed;
Reagent: butylated hydroxy anisole (BHA), dibutyl hydroxy toluene (BHT), n-propyl gallate (PC), TBHQ (TBHQ), vitamin C (VC), vitamin E (VE), citric acid are homemade food additives.
1.2 HAIYINGCAI seed oil is anti-oxidant
Adopt the constant temperature oven method, in HAIYINGCAI seed oil, add different antioxidants by selected prescription respectively, place under 60 ± 1 ℃ of constant temperatures, its peroxide value of sampling and measuring (POV) is that index is studied the influence of different antioxidants to HAIYINGCAI seed oil antioxygenic property with the peroxide value at regular intervals.
1.3 experimental technique
The method that improves the lipid-antioxidant activity performance is many, as low temperature, airtight storage, change processing conditions, use deoxidier and antioxidant etc.Wherein adding antioxidant is a kind of simple, economic and desirable method.The present invention adopts the method for adding different antioxidants to study the antioxygenic property of HAIYINGCAI seed oil.Oil-soluble inhibitor commonly used both at home and abroad at present mainly contains: TBHQ (TBHQ), dibutyl hydroxy toluene (BHT), butylated hydroxy anisole (BHA), n-propyl gallate (PG) and vitamin C (VC), vitamin E (VE), citric acid.According to the literature, the antioxygenic property of above-mentioned several antioxidants is TBHQ＞PG＞BHT＞BHA＞VE＞citric acid.
Experimental technique: precision takes by weighing HAIYINGCAI seed oil sample 100g and places dry 250ml port grinding bottle, add antioxidant a certain amount of, certain combination, fully shake up and be placed in 60 ± 1 ℃ of insulating boxs, its peroxide value of sampling analysis measuring (POV) at set intervals, reaching the required time of 10meq/kg with peroxide value (POV) is induction time and standard of comparison, the results are shown in Table 2.
The mensuration of peroxide value: the method by standard GB/T 5009 37-1996 is measured.
Table 2 antioxidant is to the influence (oxidation spare part: normal pressure, 60 ± 1 ℃) of HAIYINGCAI seed oil oxidation
| Group number | Antioxidant | Peroxide value reaches 10meq/kg required time (d) |
| 1 | Contrast | 3.2 |
| 2 | 0.015％BHT | 3.9 |
| 3 | 0.01％PG | 6.4 |
| 4 | 0.015％TBHQ | 32.5 |
| 5 | The 0.015%TBHQ+0.01% citric acid | 43.8 |
| 6 | 0.015％TBHQ+0.01％VC | 56.6 |
| 7 | The 0.015%BHT+0.01% citric acid | 6.5 |
| 8 | 0.015％BHT+0.01％VC | 7.2 |
| 9 | 0.01%TBHQ+0.01% citric acid+0.01%BHT | 31.0 |
| 10 | 0.01％TBHQ+0.01％VC+0.01％BHT | 42.5 |
| 11 | 0.015%TBHQ+0.01% citric acid+0.01%PG | 10.5 |
| 12 | 0.015％BHT+0.01％VC+0.01％PG | 10.0 |
| 13 | 0.2％VE | 35.3 |
2 results and discussion
2.1 result
Known to table 2, contrast experiment 1,2,3,4 as can be known, TBHQ has good antioxygenic property to HAIYINGCAI seed oil, antioxygenic property TBHQ＞PG＞BHT; Contrast experiment 5,6, VC and citric acid all show stronger collaborative antiopxidant effect to TBHQ, and the collaborative non-oxidizability of VC is better than citric acid; Comparative experiments 5 and 9,6 and 10 gets: the antioxygenic property of 0.015%TBHQ+0.01% citric acid is better than 0.01%TBHQ+0.01% citric acid+0.01%BHT slightly, but difference is not very big.
The antioxygenic property of respectively organizing antioxidant in the table 2 is: 0.015%TBHQ+0.01%VC＞0.015%TBHQ+0.01% citric acid＞0.01%TBHQ+0.01%VC+0.01%BHT＞0.2%VE＞0.015%TBHQ＞0.01%TBHQ+0.01% citric acid+0.01%BHT＞0.015%BHT+0.01% citric acid+0.001%PG＞0.015%BHT+0.01%VC+0.001%PG＞0.015%BHT+0.01%VC＞0.015%BHT+0.01% citric acid＞0.001%PG＞0.015%BHT.
From above-mentioned experiment as can be seen, BHT, PG, TBHQ, VC, VE, several antioxidants of citric acid can show good antiopxidant effect with oily the mixing all of HAIYINGCAI seed.
2.2 HAIYINGCAI seed oil accelerated stability test research
According to above experimental result, we add the stability that TBHQ investigates TBHQ non-oxidizability and HAIYINGCAI seed oil in HAIYINGCAI seed oil, concrete experimental technique is: precision takes by weighing HAIYINGCAI seed oil sample 100g and places dry 250ml port grinding bottle, add 0.015%TBHQ, fully shake up and be placed in 60 ± 1 ℃ of insulating boxs, its peroxide value of sampling analysis measuring (POV) at set intervals, and, the results are shown in Table 3 so that appearance luster is observed.
The report of table 3 HAIYINGCAI seed oil accelerated stability test
As can be seen from the above table, 0.015%TBHQ stablely has an obvious effect to what keep HAIYINGCAI seed oil.
Experimental example 2: the present composition is to the influence of rat fat and cholesterol
1. materials and methods
1.1 animal
90 of healthy SD male rats, body weight 200g scholar 20g, the animal quality certification number: SCXK (Soviet Union) 2004-0031.
1.2 experimental animal feed formula
Basal feed: Nanjing University of Traditional Chinese Medicine's Experimental Animal Center provides.
High lipid food: self-control, form (mass fraction): lard 15%, cholesterol 1%, basal feed 84%.This prescription is on the basal feed basis, and the cholesterol recruitment is 149.5mg/kg.
1.3 medicine
The present composition of embodiment 1, Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov provides
The present composition of embodiment 11, Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov provides
Gemfibrozil capsule, CommScope Hunan Pharmaceutical Co, lot number 040102
1.4 instrument and reagent
Triglyceride determination kit, Eastern Europe, Wenzhou bioengineering Co., Ltd product, lot number: 20040316
The cholesterol determination kit, Eastern Europe, Wenzhou bioengineering Co., Ltd product, lot number: 20040217.
The high-density LP determination reagent box, Beijing Zhongsheng Biological Engineering High Technology Company's product, lot number: 210041
The low-density LP determination reagent box, Beijing Zhongsheng Biological Engineering High Technology Company's product, lot number: 220281.
Automatic clinical chemistry analyzer, U.S. Abbott product, model: KT6HB560.
1.5 experimental technique
Rat is divided into blank group, hyperlipidemia model group, positive group, the basic, normal, high dosage group of the present composition of embodiment 1, the basic, normal, high dosage group of the present composition of embodiment 11 at random, amounts to 9 groups.The blank group is raised with basal feed; The hyperlipidemia model control group is raised with high lipid food; Positive group is raised with high lipid food, gives CI-719 108mg/kg simultaneously; Basic, normal, high 3 the dosage groups of the present composition of embodiment 1 are all raised with high lipid food, raise the present composition with embodiment 1 simultaneously, low dose group 0.22g/kg, middle dosage group 0.45g/kg, high dose group 0.90g/kg; Basic, normal, high 3 the dosage groups of the present composition of embodiment 11 are all raised with high lipid food, raise the present composition with embodiment 11 simultaneously, low dose group 0.22g/kg, middle dosage group 0.45g/kg, high dose group 0.90g/kg.
Each group is freely drunk water, and daily ingestion amount, routine weighing respectively organized in record in the process of the test.12h freely drinks water on an empty stomach before putting to death, and weighs, and the eye socket posterior vein is got blood, measures the every index of blood fat with automatic clinical chemistry analyzer behind the separation of serum.Whole test phase 24d.
1.6 the preparation of serum
Rat eye socket rear vein beard is got blood, and in the injecting tube, room temperature is placed 30min, and the centrifugal 5min of 3000r/min can get serum, and measured the same day.
2. result and analysis
2.1 the invention composition is to the influence of triglyceride in the rat blood serum (TG) and serum total cholesterol (TC), result and analysis in table 4.
Table 4 invention composition is to the influence of rat blood serum triglyceride
Compare * P＜0.05, * * P＜0.01 with the hyperlipidemia model group
As can be seen from Table 4, all there were significant differences (P＜0.01) for hyperlipidemia model group and blank group rat blood serum triglyceride and total cholesterol level, shows that hyperlipemia model of rats sets up successfully; High dose group is compared with the hyperlipidemia model group in embodiment 1, the embodiment 11 invention compositions, and statistical difference (P＜0.05 or＜0.01) is arranged; Show that the present composition can significantly suppress the rat blood serum triglyceride and serum total cholesterol content raises, promptly have and suppress the effect that blood fat raises.
2.2 the present composition is to the influence of rat blood serum HDL (HDL-C), low-density lipoprotein (LDL-C) and atherogenic index (AI).Result and analysis in table 5.
Table 5 present composition is to the influence of rat blood serum T-CHOL, HDL, low-density lipoprotein and atherogenic index
Compare * P＜0.05, * * P＜0.01 with the hyperlipidemia model group
As can be seen from Table 5, hyperlipidemia model group and blank group rat blood serum HDL (HDL-C) content have utmost point significant difference (P＜0.01), experimental example 1 and 11 middle high dose group HDL-C all have remarkable rising (P is respectively P＜0.05, P＜0.01) than hyperlipidemia model group, show the effect that has the high fat of remarkable inhibition to feed by the invention composition rat HDL-C reduces; Compare with the hyperlipidemia model group, the LDL-C of experimental example 1 and 11 high, normal, basic 3 dosage groups does not have significant difference.
By table 5 as seen, there is utmost point significant difference (P＜0.01) in atherogenic index (AI) between hyperlipidemia model group and the blank group, illustrates that the high lipid food rat arteriosclerotic danger takes place significantly increase; With the hyperlipidemia model group relatively, high dose group rat artery hardenability value (AI) tool significant difference (P is respectively P＜0.05, P＜0.01) among the embodiment 1 and 11, showing that the invention composition has reduces the harden effect of causing danger property of rat artery of feeding of high fat.
3. conclusion
The present composition has significant inhibition hyperlipidemia model animal lipid rising, and (TG TC) with the effect that suppresses the HDL-C reduction, promptly has the effect of reducing blood lipid.
Experimental example 3: the present composition is to the influence of rat fat and cholesterol
1. materials and methods
The experiment material therefor is identical with experimental example 2 with method, is subjected to the reagent thing to change the pharmaceutical composition of embodiment 3 and embodiment 18 into by the pharmaceutical composition of embodiment in the experimental example 21 and embodiment 11, is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
2. result and analysis
2.1 the present composition is to the influence of triglyceride in the rat blood serum (TG) and serum total cholesterol (TC), result and analysis in table 6.
Table 6 invention composition is to the influence of rat blood serum triglyceride
Compare * P＜0.05, * * P＜0.01 with the hyperlipidemia model group
As can be seen from Table 6, all there were significant differences (P＜0.01) for hyperlipidemia model group and blank group rat blood serum triglyceride and total cholesterol level, shows that hyperlipemia model of rats sets up successfully; High dose group is compared with the hyperlipidemia model group in embodiment 3, the embodiment 18 invention compositions, and statistical difference (P＜0.05 or＜0.01) is arranged; Show that the present composition can significantly suppress the rat blood serum triglyceride and serum total cholesterol content raises, promptly have and suppress the effect that blood fat raises.
2.2 the present composition is to the influence of rat blood serum HDL (HDL-C), low-density lipoprotein (LDL-C) and atherogenic index (AI).Result and analysis in table 7.
Table 7 present composition is to the influence of rat blood serum T-CHOL, HDL, low-density lipoprotein and atherogenic index
Compare * P＜0.05, * * P＜0.01 with the hyperlipidemia model group
As can be seen from Table 7, hyperlipidemia model group and blank group rat blood serum HDL (HDL-C) content have utmost point significant difference (P＜0.01), experimental example 3 and 18 middle high dose group HDL-C all have remarkable rising (P is respectively P＜0.05, P＜0.01) than hyperlipidemia model group, show the effect that has the high fat of remarkable inhibition to feed by the invention composition rat HDL-C reduces; Compare with the hyperlipidemia model group, the LDL-C of experimental example 3 and 18 high, normal, basic 3 dosage groups does not have significant difference.
By table 7 as seen, there is utmost point significant difference (P＜0.01) in atherogenic index (AI) between hyperlipidemia model group and the blank group, illustrates that the high lipid food rat arteriosclerotic danger takes place significantly increase; With the hyperlipidemia model group relatively, high dose group rat artery hardenability value (AI) tool significant difference (P is respectively P＜0.05, P＜0.01) among the embodiment 3 and 18, showing that the invention composition has reduces the harden effect of causing danger property of rat artery of feeding of high fat.
3. conclusion
The present composition has significant inhibition hyperlipidemia model animal lipid rising, and (TG TC) with the effect that suppresses the HDL-C reduction, promptly has the effect of reducing blood lipid.
Experimental example 4: the present composition is to the influence of rat fat and cholesterol
1. materials and methods
The experiment material therefor is identical with experimental example 2 with method, is subjected to the reagent thing to change the pharmaceutical composition of embodiment 20 and embodiment 22 into by the pharmaceutical composition of embodiment in the experimental example 21 and embodiment 11, is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
2. result and analysis
2.1 the invention composition is to the influence of triglyceride in the rat blood serum (TG) and serum total cholesterol (TC), result and analysis in table 8.
Table 8 invention composition is to the influence of rat blood serum triglyceride
Compare * P＜0.05, * * P＜0.01 with the hyperlipidemia model group
As can be seen from Table 8, all there were significant differences (P＜0.01) for hyperlipidemia model group and blank group rat blood serum triglyceride and total cholesterol level, shows that hyperlipemia model of rats sets up successfully; High dose group is compared with the hyperlipidemia model group in embodiment 20, the embodiment 22 invention compositions, and statistical difference (P＜0.05 or＜0.01) is arranged; Show that the present composition can significantly suppress the rat blood serum triglyceride and serum total cholesterol content raises, promptly have and suppress the effect that blood fat raises.
2.2 the present composition is to the influence of rat blood serum HDL (HDL-C), low-density lipoprotein (LDL-C) and atherogenic index (AI).Result and analysis in table 9.
Table 9 present composition is to the influence of rat blood serum T-CHOL, HDL, low-density lipoprotein and atherogenic index
Compare * P＜0.05, * * P＜0.01 with the hyperlipidemia model group
As can be seen from Table 9, hyperlipidemia model group and blank group rat blood serum HDL (HDL-C) content have utmost point significant difference (P＜0.01), experimental example 20 and 22 middle high dose group HDL-C all have remarkable rising (P is respectively P＜0.05, P＜0.01) than hyperlipidemia model group, show the effect that has the high fat of remarkable inhibition to feed by the invention composition rat HDL-C reduces; Compare with the hyperlipidemia model group, the LDL-C of experimental example 20 and 22 high, normal, basic 3 dosage groups does not have significant difference.
By table 9 as seen, there is utmost point significant difference (P＜0.01) in atherogenic index (AI) between hyperlipidemia model group and the blank group, illustrates that the high lipid food rat arteriosclerotic danger takes place significantly increase; With the hyperlipidemia model group relatively, high dose group rat artery hardenability value (AI) tool significant difference (P is respectively P＜0.05, P＜0.01) among the embodiment 20 and 22, showing that the invention composition has reduces the harden effect of causing danger property of rat artery of feeding of high fat.
3. conclusion
The present composition has significant inhibition hyperlipidemia model animal lipid rising, and (TG TC) with the effect that suppresses the HDL-C reduction, promptly has the effect of reducing blood lipid.
Experimental example 5: the present composition is to the influence of blood glucose in diabetic rats
1 materials and methods
1.1 material
4 monthly ages cleaning level wistar rat, male, body weight 200 ± 20g, provide by Nanjing Medical University's Experimental Animal Center, Jiangsu Province animal quality quality certification numbering (2004B021) is raised in 25 ℃ ± 1 ℃ constant temperature and humidity are 40%～70% air conditioner surroundings, change bedding and padding every day, specially raise the chamber, and the special messenger is responsible for; High lipid food and the pure water of use after strict sterilization fed, and all animal sub-cage rearings guarantee that animal used as test has enough activity spaces, can freely ingest, take the photograph water.
Streptozotocin (STZ), U.S. SIGMA company product, lot number 024k1211;
Blood glucose meter, Johnson Co.'s product, model: L730355.
Tes-Tape, Johnson Co.'s product.
1.2 medicine
The present composition of embodiment 3 is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
The present composition of embodiment 18 is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
The gliclazide sheet, Tianjin Hua Jin pharmaceutical factory, lot number 031116
1.3 method
Cleaning level SD rat, male, adaptability was fed 7 days, and through the Tes-Tape test, what glucose in urine was negative is selected in totally 180, is divided into two groups at random, the 1st group 20, the 2nd group 160, gives conventional feed the 1st group of every day; The 2nd group is the modeling group, after 4 all high lipid foods are fed, modeling group rat gives fasting and can't help water 18h, (Streptozotocin is dissolved in the sodium citrate buffer solution (pH4.5) of 1mmol/L STZ solution with 1%, be configured to concentration and be 1% solution, the lucifuge ice bath, now with the current) inject with the dosage disposable celiac of 35mg/kg.Respectively at injection back 12h, 24h, 72h surveys tail vein sugar value, select blood sugar to continue greater than 80 of the rats of 16.7mmol/L, be divided into 8 groups at random, be respectively model group, positive group, the high, medium and low dosage group of the present composition of embodiment 3, the high, medium and low dosage group of the present composition of embodiment 18.The 1st group of lumbar injection equal-volume citrate buffer solution.After this get 10 for the normal control group for 1 group, give physiological saline and irritate stomach by 5ml/kg dosage, model group is given high lipid food, and positive group is raised with high lipid food, gives gliclazide sheet 21.6mg/kg simultaneously; Basic, normal, high 3 the dosage groups of the present composition of embodiment 3 are all raised with high lipid food, raise the present composition with embodiment 3 simultaneously, low dose group 0.22g/kg, middle dosage group 0.45g/kg, high dose group 0.90g/kg; Basic, normal, high 3 the dosage groups of the present composition of embodiment 18 are all raised with high lipid food, raise the present composition with embodiment 18 simultaneously, low dose group 0.22g/kg, middle dosage group 0.45g/kg, high dose group 0.90g/kg.1 time/d, continuous 4 weeks.During carrying out, experiment all arbitrarily drinks water.
1.4 observation index
Observe situation such as rats eating, drinking-water, activity and keep a record every day in experimentation, weighed in 1 week 1 time and survey random blood sugar 1 time.When experiment finishes, cut tail and get blood survey random blood sugar.
1.5 statistical analysis
Measurement data is with (X ± s) expression uses the variance analysis (ANOVA) in the SPSS11.0 statistical software to test.
2 experimental results
Table 10 administration 4 week the back model group with treatment group rat blood sugar, the comparison of body weight situation (X ± S, n=10)
Compare * * P＜0.01, * P＜0.05 with model group
The present composition is to the influence of diabetes rat body weight and blood glucose value
Each group of the normal control group and the present composition does not have animal dead at experimental session, and model group has 2 rats deaths in experimentation.Each is organized the modeling rat body weight and is starkly lower than normal rats, and the rat body weight of high dose group is compared with model group in embodiment 3 and the 18 invention compositions, has significant difference (P is respectively P＜0.01, P＜0.05).
Model group rat blood sugar level is compared with the normal control group, and there were significant differences (P＜0.01).High dose group has the effect of certain reduction blood sugar in embodiment 3 and the 18 invention compositions, compare with model group, significant difference (P is respectively P＜0.01, P＜0.05) is arranged, show the effect that the present composition has certain adjusting blood glucose in diabetic rats.
Experimental example 6: the present composition is to the influence of blood glucose in diabetic rats
1 materials and methods
The experiment material therefor is identical with experimental example 5 with method, is subjected to the reagent thing to change the pharmaceutical composition of embodiment 1 and embodiment 11 into by the pharmaceutical composition of embodiment in the experimental example 53 and embodiment 18, is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
2 experimental results
Experimental result sees the following form:
Table 11 administration 4 week the back model group with treatment group rat blood sugar, the comparison of body weight situation (X ± S, n=10)
Compare * * P＜0.01, * P＜0.05 with model group
The present composition is to the influence of diabetes rat body weight and blood glucose value
Each group of the normal control group and the present composition does not have animal dead at experimental session, and model group has 1 rats death in experimentation.Each is organized the modeling rat body weight and is starkly lower than normal rats, and the rat body weight of high dose group is compared with model group in embodiment 1 and the 11 invention compositions, has significant difference (P is respectively P＜0.01, P＜0.05).
Model group rat blood sugar level is compared with the normal control group, and there were significant differences (P＜0.01).High dose group has the effect of certain reduction blood sugar in embodiment 1 and the 11 invention compositions, compare with model group, significant difference (P is respectively P＜0.01, P＜0.05) is arranged, show the effect that the present composition has certain adjusting blood glucose in diabetic rats.
Experimental example 7: the present composition is to the influence of blood glucose in diabetic rats
1 materials and methods
The experiment material therefor is identical with experimental example 5 with method, is subjected to the reagent thing to change the pharmaceutical composition of embodiment 20 and embodiment 22 into by the pharmaceutical composition of embodiment in the experimental example 53 and embodiment 18, is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
2 experimental results
Experimental result sees the following form:
Table 12 administration 4 week the back model group with treatment group rat blood sugar, the comparison of body weight situation (X ± S, n=10)
Compare * * P＜0.01, * P＜0.05 with model group
The present composition is to the influence of diabetes rat body weight and blood glucose value
Each group of the normal control group and the present composition does not have animal dead at experimental session, and model group has 1 rats death in experimentation.Each is organized the modeling rat body weight and is starkly lower than normal rats, and the rat body weight of high dose group is compared with model group in embodiment 20 and the 22 invention compositions, has significant difference (P is respectively P＜0.01, P＜0.05).
Model group rat blood sugar level is compared with the normal control group, and there were significant differences (P＜0.01).High dose group has the effect of certain reduction blood sugar in embodiment 20 and the 22 invention compositions, compare with model group, significant difference (P is respectively P＜0.01, P＜0.05) is arranged, show the effect that the present composition has certain adjusting blood glucose in diabetic rats.
Experimental example 8: the present composition is to mouse blood fat and Immune Effects
1 experiment material
1.1 medicine
The present composition of embodiment 20 is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov;
The present composition of embodiment 22 is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov;
Gemfibrozil capsule, CommScope Hunan Pharmaceutical Co, lot number 040102
Lentinan (world is glad), Nanjing Zhenzhong Biological Engineering Co., Ltd, lot number: 030512
Endoxan is provided by Hengrui Medicine Co., Ltd., Jiangsu Prov., lot number: 04090321;
Sodium carbonate, one factory provides by the Nanjing chemical reagent, lot number: 041111101.
1.2 animal used as test
A cleaning level mouse is provided by Nanjing Medical University's Experimental Animal Center, the animal quality certification number: SCXK (Soviet Union) 2004-0031.
2 experimental techniques and result
2.1 influence to the high fat of mouse
2.1.1 experimental technique: get 90 of mouse, male, 18～22g is divided into 9 groups, i.e. the normal control group: give edible oil 20ml/kg at random; Model group: give edible oil 20ml/kg; Positive group: give CI-719 156mg/kg; The basic, normal, high dosage group of the present composition of embodiment 20 gives present composition 0.33ml/kg, 0.65ml/kg, the 1.30ml/kg of embodiment 20 respectively; The basic, normal, high dosage group of the present composition of embodiment 22 gives present composition 0.33ml/kg, 0.65ml/kg, the 1.30ml/kg of embodiment 22 respectively.Each group is subjected to the reagent thing respectively, every day 1 time, totally 5 days, in the last two hours after administration, except that the normal control group, all the other respectively organize all lumbar injection 75% egg-nog 0.5ml, and posterior orbit was got blood (fasting 12 hours) in 20 hours, separation of serum detects serum total cholesterol (TC) and triglyceride (TG) level in the serum.
2.1.2 experimental result: see Table 13
Table 13 invention composition to the influence of mouse TC, TG (X ± S, n=10)
Compare * * P＜0.01, * P＜0.05 with model group
Compare with the normal control group, model group mice serum TC and TG level all have significant difference (P＜0.01).Compare with model group, high dose has certain reduction serum TC, the effect of TG (P is respectively P＜0.05, P＜0.01) in the invention composition of embodiment 20,22, shows that the invention composition has the effect of the high fat mouse of certain reduction blood fat.
2.2 influence to hypoimmunity mouse carbon particle clearance
2.2.1 experimental technique: get 90 of mouse, male and female half and half, 18～22g is divided into 9 groups, i.e. the normal control group: give edible oil 20ml/kg at random; Model group: give edible oil 20ml/kg; Positive group: give lentinan 0.13mg/kg; The basic, normal, high dosage group of the present composition of embodiment 20 gives invention composition 0.33ml/k g, 0.65ml/kg, the 1.30ml/kg of embodiment 20 respectively; The basic, normal, high dosage group of the invention composition of embodiment 22 gives invention composition 0.33ml/kg, 0.65ml/kg, the 1.30ml/kg of embodiment 22 respectively.Every day 1 time, totally 8 days, except that normal group, all the other each groups are hypodermic injection endoxan 75mg/kg in first three day administration all, 30min after the last administration, mouse is tail vein injection 20% india ink 0.1ml/kg immediately, and in 2,10min respectively eye socket get blood 20ul, add and fill in the test tube of 2ml 0.1% sodium carbonate normal saline solution, survey its OD value in the 680nm place, put to death mouse, get liver, spleen, thymus gland, weigh, calculate respectively and clean up index K, phagocytic index A.
2.2.2 experimental result: see Table 14 and table 15
Table 14 invention composition to the influence of mouse immune (X ± S, n=10)
Compare * P＜0.05, * * P＜0.01 with model group
Compare with the normal control group, model group mouse spleen exponential sum thymus index all significantly reduces (P＜0.01), compare with model group, the invention composition high dose group of embodiment 20,22 has the certain increase index and spleen index and the effect of thymus index, and significant difference (P＜0.05) is arranged.
Table 15 invention composition to the influence of clearance in mice index, phagocytic index (X ± S, n=10)
Compare * P＜0.05, * * P＜0.01 with model group
Compare with the normal control group, model group is cleaned up the exponential sum phagocytic index and is all significantly reduced (P＜0.01), compare with model group, the high dose group clearance in mice exponential sum phagocytic index that can raise in the present composition of embodiment 20,22, has significant difference (P is respectively P＜0.05, P＜0.01).
From above experiment as can be seen the present composition also have certain reducing blood lipid and strengthen the effect of immunity.
Experimental example 9: the present composition is to mouse blood fat and Immune Effects
2.1 influence to the high fat of mouse
2.1.1 experiment material and method
It is identical with experimental example 8 with method to test used experiment material, is subjected to the reagent thing to change the pharmaceutical composition of embodiment 1 and embodiment 11 into by the pharmaceutical composition of embodiment in the experimental example 8 20 and embodiment 22, is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
2.1.2 experimental result
Experimental result sees Table 16
Table 16 invention composition to the influence of mouse TC, TG (X ± S, n=10)
Compare * * P＜0.01, * P＜0.05 with model group
Compare with the normal control group, model group mice serum TC and TG level all have significant difference (P＜0.01).Compare with model group, high dose has certain reduction serum TC, the effect of TG (P is respectively P＜0.05, P＜0.01) in the invention composition of embodiment 1,11, shows that the invention composition has the effect of the high fat mouse of certain reduction blood fat.
2.2 influence to hypoimmunity mouse carbon particle clearance
2.2.1 experimental technique
Used experiment material is identical with experimental example 8 with method, is subjected to the reagent thing to change embodiment 1 and embodiment 11 into by embodiment in the experimental example 8 20 and embodiment 22, is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
2.2.2 experimental result: see Table 17 and table 18
Table 17 invention composition to the influence of mouse immune (X ± S, n=10)
Compare * P＜0.05, * * P＜0.01 with model group
Compare with the normal control group, model group mouse spleen exponential sum thymus index all significantly reduces (P＜0.01), compare with model group, the invention composition high dose group of embodiment 1,11 has the certain increase index and spleen index and the effect of thymus index, and significant difference (P＜0.05) is arranged.
Table 18 invention composition to the influence of clearance in mice index, phagocytic index (X ± S, n=10)
Compare * P＜0.05, * * P＜0.01 with model group
Compare with the normal control group, model group is cleaned up the exponential sum phagocytic index and is all significantly reduced (P＜0.01), compare with model group, the high dose group clearance in mice exponential sum phagocytic index that can raise in the present composition of embodiment 1,11, has significant difference (P is respectively P＜0.05, P＜0.01).
From above experiment as can be seen the present composition also have certain reducing blood lipid and strengthen the effect of immunity.
Experimental example 10: the present composition is to mouse blood fat and Immune Effects
2.1 influence to the high fat of mouse
2.1.1 experiment material and method
Used experiment material is identical with experimental example 8 with method, is subjected to the reagent thing to change embodiment 3 and embodiment 18 into by embodiment in the experimental example 8 20 and embodiment 22, is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
2.1.2 experimental result
Experimental result: see Table 19
Table 19 invention composition to the influence of mouse TC, TG (X ± S, n=10)
Compare * * P＜0.01, * P＜0.05 with model group
Compare with the normal control group, model group mice serum TC and TG level all have significant difference (P＜0.01).Compare with model group, high dose has certain reduction serum TC, the effect of TG (P is respectively P＜0.05, P＜0.01) in the invention composition of embodiment 3,18, shows that the invention composition has the effect of the high fat mouse of certain reduction blood fat.
2.2 influence to hypoimmunity mouse carbon particle clearance
2.2.1 experimental technique
Used experiment material is identical with experimental example 8 with method, is subjected to the reagent thing to change embodiment 3 and embodiment 18 into by embodiment in the experimental example 8 20 and embodiment 22, is provided by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
2.2.2 experimental result: see Table 20 and table 21
Table 20 invention composition to the influence of mouse immune (X ± S, n=10)
Compare * P＜0.05, * * P＜0.01 with model group
Compare with the normal control group, model group mouse spleen exponential sum thymus index all significantly reduces (P＜0.01), compare with model group, the invention composition high dose group of embodiment 3,18 has the certain increase index and spleen index and the effect of thymus index, and significant difference (P＜0.05) is arranged.
Table 21 invention composition to the influence of clearance in mice index, phagocytic index (X ± S, n=10)
Compare * P＜0.05, * * P＜0.01 with model group
Compare with the normal control group, model group is cleaned up the exponential sum phagocytic index and is all significantly reduced (P＜0.01), compare with model group, the high dose group clearance in mice exponential sum phagocytic index that can raise in the present composition of embodiment 3,18, has significant difference (P is respectively P＜0.05, P＜0.01).
From above experiment as can be seen the present composition also have certain reducing blood lipid and strengthen the effect of immunity.
Embodiment 1: present composition soft capsule
HAIYINGCAI seed oil 500g, butylated hydroxy anisole 0.077g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 2: present composition soft capsule
HAIYINGCAI seed oil 500g, TBHQ 0.100g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 3: present composition soft capsule
HAIYINGCAI seed oil 500g, dibutyl hydroxy toluene 0.083g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 4: present composition soft capsule
HAIYINGCAI seed oil 500g, n-propyl gallate 0.072g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 5: present composition soft capsule
HAIYINGCAI seed oil 500g, vitamin C 0.063g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.0.013％
Embodiment 6: present composition soft capsule
HAIYINGCAI seed oil 500g, vitamin E 0.034g, n-propyl gallate 0.034g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 7: present composition soft capsule
HAIYINGCAI seed oil 500g, citric acid 0.032g, n-propyl gallate 0.035g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 8: present composition soft capsule
HAIYINGCAI seed oil 500g, citric acid 0.100g, n-propyl gallate 0.050g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 9: present composition soft capsule
HAIYINGCAI seed oil 500g, vitamin E 0.1g, n-propyl gallate 0.1g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 10: present composition soft capsule
HAIYINGCAI seed oil 500g, vitamin C 0.25g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.5g HAIYINGCAI seed oil/grain), twice of every day.
Embodiment 11: present composition soft capsule
HAIYINGCAI seed oil 299.75g, fish oil 200.00g, butylated hydroxy anisole 0.25g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.3g HAIYINGCAI seed oil, fish oil 0.2g/ grain), twice of every day.
Embodiment 12: present composition soft capsule
HAIYINGCAI seed oil 324.75g, maize germ 100g, Semen Juglandis oil 75.00g, vitamin E 0.25g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.32g HAIYINGCAI seed oil, maize germ 0.1g, Semen Juglandis oil 0.08g/ grain), twice of every day.
Embodiment 13: present composition soft capsule
HAIYINGCAI seed oil 349.8g, evening primrose oil 150.00g, TBHQ 0.2g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.35g HAIYINGCAI seed oil, evening primrose oil 0.15g/ grain), twice of every day.
Embodiment 14: present composition soft capsule
HAIYINGCAI seed oil 374.75g, olive oil 80g, mustard caul-fat 45.00g, citric acid 0.25g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.38g HAIYINGCAI seed oil, olive oil 0.08g, mustard caul-fat 0.04g/ grain), twice of every day.
Embodiment 15: present composition soft capsule
HAIYINGCAI seed oil 374.85g, perilla herb oil 125.00g, butylated hydroxy anisole 0.15g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.37g HAIYINGCAI seed oil, perilla herb oil 0.13g/ grain), twice of every day.
Embodiment 16: present composition soft capsule
HAIYINGCAI seed oil 399.85g, evening primrose oil 50g, perilla herb oil 50.00g, butylated hydroxy anisole 0.15g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.40g HAIYINGCAI seed oil, evening primrose oil 0.05g, perilla herb oil 0.05g/ grain), twice of every day.
Embodiment 17: present composition soft capsule
HAIYINGCAI seed oil 424.90g, tea oil 75.00g, n-propyl gallate 0.10g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.43g HAIYINGCAI seed oil, tea oil 0.07g/ grain), twice of every day.
Embodiment 18: present composition soft capsule
HAIYINGCAI seed oil 449.9g, evening primrose oil 50.00g, butylated hydroxy anisole 0.1g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.45g HAIYINGCAI seed oil, evening primrose oil 0.05g/ grain), twice of every day.
Embodiment 19: present composition soft capsule
HAIYINGCAI seed oil 474.95g, palm oil 25.00g, vitamin C 0.05g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.47g HAIYINGCAI seed oil, palm oil 0.03g/ grain), twice of every day.
Embodiment 20: present composition soft capsule
HAIYINGCAI seed oil 474.95g, perilla herb oil 25.00g, butylated hydroxy anisole 0.05g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 2～5 (0.47g HAIYINGCAI seed oil, perilla herb oil 0.03g/ grain), twice of every day.
Embodiment 21: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, butylated hydroxy anisole 0.15g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, add butylated hydroxy anisole 0.15g, add about 8900ml of water and an amount of emulsifying agent, adjust total amount, stir evenly, filter to 10000ml, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 22: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, TBHQ 0.16g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, add butylated hydroxy anisole 0.16g, add about 8900ml of water and an amount of emulsifying agent, adjust total amount, stir evenly, filter to 10000ml, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 23: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, citric acid 0.14g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, add butylated hydroxy anisole 0.14g, add about 8900ml of water and an amount of emulsifying agent, adjust total amount, stir evenly, filter to 10000ml, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 24: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, dibutyl hydroxy toluene 0.13g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, add dibutyl hydroxy toluene 0.13g, add about 8900ml of water and an amount of emulsifying agent, adjust total amount, stir evenly, filter to 10000ml, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 25: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, n-propyl gallate 0.17g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, add n-propyl gallate 0.17g, add about 8900ml of water and an amount of emulsifying agent, adjust total amount, stir evenly, filter to 10000ml, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 26: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, vitamin C 0.18g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, add vitamin C 0.18g, add about 8900ml of water and an amount of emulsifying agent, adjust total amount, stir evenly, filter to 10000ml, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 27: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, vitamin E 0.19g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, add vitamin E 0.19g, add about 8900ml of water and an amount of emulsifying agent, adjust total amount, stir evenly, filter to 10000ml, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 28: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, citric acid 0.25g, n-propyl gallate 0.25g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, citric acid 0.25g, n-propyl gallate 0.25g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 29: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, vitamin E 0.15g, n-propyl gallate 0.15g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, vitamin E 0.15g, n-propyl gallate 0.15g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 30: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, vitamin C 0.1g, emulsifying agent is an amount of, makes oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 1000g, vitamin C 0.1g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, and can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (1.0g HAIYINGCAI seed oil /), twice of every day.
Embodiment 31: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 800g, vitamin E 0.19g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 600g, fish oil 400g, butylated hydroxy anisole 0.5g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (0.6g HAIYINGCAI seed oil, fish oil 0.4g/ props up), twice of every day.
Embodiment 32: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, vitamin E 0.19g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 650g, maize germ 150g, Semen Juglandis oil 200g, vitamin E 0.5g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stir evenly, filter can, packing, make 1000 of oral liquids, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (Semen Juglandis oil 0.2g/ props up for 0.65g HAIYINGCAI seed oil, maize germ 0.15g), twice of every day.
Embodiment 33: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 1000g, vitamin E 0.19g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 700g, evening primrose oil 300g, TBHQ 0.4g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each l～2 (0.7g HAIYINGCAI seed oil, evening primrose oil 0.3g/ props up), twice of every day.
Embodiment 34: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 750g, olive oil 150g, mustard caul-fat 100g, citric acid 0.4g,, emulsifying agent is an amount of, makes oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 750g, olive oil 150g, mustard caul-fat 100.00g, citric acid 0.4g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stir evenly, filter can, packing, make 1000 of oral liquids, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (mustard caul-fat 0.1g/ props up for 0.75g HAIYINGCAI seed oil, olive oil 0.15g), twice of every day.
Embodiment 35: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 750g, perilla herb oil 250g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 750g, perilla herb oil 250g, butylated hydroxy anisole 0.3g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (0.75g HAIYINGCAI seed oil, perilla herb oil 0.25g/ props up), twice of every day.
Embodiment 36: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 800g, evening primrose oil 100g, perilla herb oil 100g, butylated hydroxy anisole 0.3g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 800g, evening primrose oil 100g, perilla herb oil 100g, butylated hydroxy anisole 0.3g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stir evenly, filter can, packing, make 1000 of oral liquids, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (perilla herb oil 0.1g/ props up for 0.8g HAIYINGCAI seed oil, evening primrose oil 0.1g), twice of every day.
Embodiment 37: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 850g, tea oil 150g, n-propyl gallate 0.2g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 850g, tea oil 150g, n-propyl gallate 0.2g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (0.85g HAIYINGCAI seed oil, tea oil 0.15g/ props up), twice of every day.
Embodiment 38: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 900g, evening primrose oil 100g, butylated hydroxy anisole 0.2g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 900g, evening primrose oil 100g, butylated hydroxy anisole 0.2g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (0.9g HAIYINGCAI seed oil, evening primrose oil 0.1g/ props up), twice of every day.
Embodiment 39: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 950g, palm oil 50g, vitamin C 0.1g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
Get HAIYINGCAI seed oil 950g, palm oil 50g, vitamin C 0.1g adds about 8900ml of water and an amount of emulsifying agent, adjusts total amount to 10000ml, stirs evenly, filter, can, 1000 of oral liquids are made in packing, every 10ml, sterilization promptly gets oral liquid.
Usage and dosage: oral, each 1～2 (0.95g HAIYINGCAI seed oil, palm oil 0.05g/ props up), twice of every day.
Embodiment 40: the preparation of present composition oral liquid
1. fill a prescription
HAIYINGCAI seed oil 950g, perilla herb oil 50g, butylated hydroxy anisole 0.1g, emulsifying agent are an amount of, make oral liquid 10000ml.
2. method for making
HAIYINGCAI seed oil 950g, perilla herb oil 50g, butylated hydroxy anisole 0.1g fully stirs evenly and promptly gets soft capsule content, and pressing or dropping preparation method are made 1000 of soft capsules, every 0.5g.
Usage and dosage: oral, each 1～2 (0.95g HAIYINGCAI seed oil, perilla herb oil 0.05g/ props up), twice of every day.
Claims (9)
1, a kind of composition that has reducing blood lipid, adjusting blood sugar, strengthens immunity is characterized in that said composition is to be made by the raw material that comprises following weight portion:
(1) HAIYINGCAI seed oil 99.95%～99.99%,
(2) antioxidant 0.01%～0.05%;
Wherein, the antioxidant in the composition is one or more in butylated hydroxy anisole, TBHQ, dibutyl hydroxy toluene, n-propyl gallate, vitamin C, vitamin E, the citric acid;
Wherein, the HAIYINGCAI seed oil of 5%～40% weight portion can substitute with in fish oil, evening primrose oil, perilla herb oil, tea oil, palm oil, maize germ, Semen Juglandis oil, olive oil, the mustard caul-fat one or more in the said composition.
2, composition as claimed in claim 1 is characterized in that said composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 99.95%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.05%.
3, composition as claimed in claim 1 is characterized in that said composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 99.97%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.03%.
4, composition as claimed in claim 1 is characterized in that said composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 99.99%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.01%.
5, composition as claimed in claim 1 is characterized in that said composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 59.95%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.05%,
(3) fish oil and evening primrose oil and/or perilla herb oil and/or tea oil and/or palm oil and/or maize germ and/or Semen Juglandis oil and/or olive oil and/or mustard caul-fat 40%.
6, composition as claimed in claim 1 is characterized in that said composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 74.97%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.03%,
(3) fish oil and evening primrose oil and/or perilla herb oil and/or tea oil and/or palm oil and/or maize germ and/or Semen Juglandis oil and/or olive oil and/or mustard caul-fat 25%.
7, composition as claimed in claim 1 is characterized in that said composition is to be made by the raw material of following weight portion:
(1) HAIYINGCAI seed oil 94.99%,
(2) butylated hydroxy anisole and TBHQ and/or dibutyl hydroxy toluene and/or n-propyl gallate and/or vitamin C and/or vitamin E and/or citric acid 0.01%,
(3) fish oil and evening primrose oil and/or perilla herb oil and/or tea oil and/or palm oil and/or maize germ and/or Semen Juglandis oil and/or olive oil and/or mustard caul-fat 5%.
8,, it is characterized in that said composition is prepared into soft capsule as the described composition of claim 1～7.
9,, it is characterized in that said composition is prepared into oral liquid formulations as the described composition of claim 1～7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100933766A CN101558794A (en) | 2008-04-15 | 2008-04-15 | Composition with functions of lowering blood lipid and regulating blood sugar and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100933766A CN101558794A (en) | 2008-04-15 | 2008-04-15 | Composition with functions of lowering blood lipid and regulating blood sugar and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101558794A true CN101558794A (en) | 2009-10-21 |
Family
ID=41217908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100933766A Pending CN101558794A (en) | 2008-04-15 | 2008-04-15 | Composition with functions of lowering blood lipid and regulating blood sugar and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101558794A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919452A (en) * | 2010-08-03 | 2010-12-22 | 刘立 | Compound oil health food |
| CN102106534A (en) * | 2010-12-28 | 2011-06-29 | 北京同仁堂健康药业股份有限公司 | Composition for assisting in lowering blood fat and preparation method thereof |
| CN102308915A (en) * | 2011-07-26 | 2012-01-11 | 上海交通大学 | Anti-oxidant composition for improving animal immune function and preparation method thereof |
| CN104055123A (en) * | 2014-05-25 | 2014-09-24 | 宁波市成大机械研究所 | Gamma-linolenic acid containing deep sea fish oil soft capsule |
| CN104351359A (en) * | 2014-10-29 | 2015-02-18 | 颍上县永祥旱粮研究所 | Healthy rapeseed oil |
| CN104543047A (en) * | 2015-02-09 | 2015-04-29 | 陕西大统投资股份有限公司 | Preservation method of cold-squeezed walnut oil |
| CN104970360A (en) * | 2015-06-19 | 2015-10-14 | 贵州神奇药物研究院 | Health-care food for reducing blood lipid and preparation method of health-care food |
| CN105125755A (en) * | 2015-08-13 | 2015-12-09 | 长春康彼达科技有限公司 | Auxiliary lipid-lowering drug and preparation method thereof |
-
2008
- 2008-04-15 CN CNA2008100933766A patent/CN101558794A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919452A (en) * | 2010-08-03 | 2010-12-22 | 刘立 | Compound oil health food |
| CN101919452B (en) * | 2010-08-03 | 2013-01-09 | 刘立 | Compound oil health food |
| CN102106534A (en) * | 2010-12-28 | 2011-06-29 | 北京同仁堂健康药业股份有限公司 | Composition for assisting in lowering blood fat and preparation method thereof |
| CN102308915A (en) * | 2011-07-26 | 2012-01-11 | 上海交通大学 | Anti-oxidant composition for improving animal immune function and preparation method thereof |
| CN104055123A (en) * | 2014-05-25 | 2014-09-24 | 宁波市成大机械研究所 | Gamma-linolenic acid containing deep sea fish oil soft capsule |
| CN104351359A (en) * | 2014-10-29 | 2015-02-18 | 颍上县永祥旱粮研究所 | Healthy rapeseed oil |
| CN104543047A (en) * | 2015-02-09 | 2015-04-29 | 陕西大统投资股份有限公司 | Preservation method of cold-squeezed walnut oil |
| CN104970360A (en) * | 2015-06-19 | 2015-10-14 | 贵州神奇药物研究院 | Health-care food for reducing blood lipid and preparation method of health-care food |
| CN105125755A (en) * | 2015-08-13 | 2015-12-09 | 长春康彼达科技有限公司 | Auxiliary lipid-lowering drug and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101558794A (en) | Composition with functions of lowering blood lipid and regulating blood sugar and preparation method thereof | |
| RU2093996C1 (en) | Method of addition to child's nutrient mixture of docosahexanoic and arachidonic acids (versions) and composition (versions) | |
| DE69935995T2 (en) | POLYUNGATURATED FATTY ACIDS NUTRITIONAL SUPPLEMENT | |
| Fedorova-Dahms et al. | Safety evaluation of Algal Oil from Schizochytrium sp. | |
| CN101185465B (en) | Fat compositions and uses thereof | |
| CN101766235A (en) | Blend oil, preparation method and application thereof | |
| CN108402188A (en) | A kind of edible oil and preparation method for strengthening supplement DHA and alpha-linolenic acid | |
| CN102599270A (en) | Health flavoring oil being rich in alpha-linolenic acid and preparation method thereof | |
| CN102342330A (en) | Oil and fat composition containing diglyceride and use thereof | |
| Koletzko et al. | Fatty acid composition of mature human milk in Nigeria | |
| CN101554190B (en) | Edible oil containing two types of essential fatty acid | |
| CN101088349B (en) | Edible blend oil containing docosahexenoic acid | |
| CN107794230A (en) | Yeast strain and its in the aborning purposes of lipid | |
| CN105079009A (en) | Composition for preventing and /or treating cardiovascular and cerebrovascular diseases | |
| Aslam et al. | Protective effect of sesame (sesamum indicum) seed oil against hypercholesterolemic in sprague-dawley male rats | |
| CN105434331B (en) | A kind of self-emulsifying Co-Q10 finish and its preparation method and application | |
| CN102416056A (en) | Compound nanoemulsion oral liquid for reducing blood fat and preparation method thereof | |
| CN101579020A (en) | Edible oil without saturated fatty acid | |
| CN110141564A (en) | A kind of glyceride mixture and its preparation method and application rich in polyunsaturated fatty acid | |
| US20100239660A1 (en) | Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions | |
| Krámer et al. | The Effect of Different Factors on the Composition of Human Milk and its Variations. III. Effect of Dietary Fats on the Lipid Composition of Human Milk: Wirkung verschiedener Faktoren auf die Zusammensetzung menschlicher Milch. III. Wirkung des Nahrungsfettes auf den Fettgehalt der menschlichen Milch.–Effet de différents facteurs sur la composition du lait humain et ses variations. III. Effet des graisses alimentaires sur la composition en lipides du lait humain | |
| Horrobin et al. | The effects of evening primrose oil, safflower oil and paraffin on plasma fatty acid levels in humans: choice of an appropriate placebo for clinical studies on primrose oil | |
| CN106418542A (en) | Health-care product having function of regulating blood lipids and preparation method thereof | |
| CN104740090A (en) | Functional grease composition with improvement effects on atherosclerosis | |
| CN102106534A (en) | Composition for assisting in lowering blood fat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1134999 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091021 |